Century Therapeutics, Inc.
Century Therapeutics, Inc. (IPSC) Free Cash Flow & Analysis
Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.
IPSC · free cash flow · updated Jun 9, 2026
Core FCF metrics
IPSC · FCF · TTM · margin & CAGRFree cash flow was −$104.7M for FY2025 (fiscal year ending 2025-12-31), up 5.0% year-over-year The FCF margin was -95.9%.
Annual free cash flow history
Annual free cash flow data
FCF valuation metrics
IPSC · P/FCF · FCF yield · FCF per shareCentury Therapeutics, Inc. (IPSC) reported negative free cash flow of −$0.10B. FCF-based valuation ratios are not meaningful when FCF is negative.
FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.
Cash flow statement summary
IPSC · cash flow statement · operating / investing / financingFor FY2025, Century Therapeutics, Inc. generated −$103.9M in operating cash flow and spent 1M in capital expenditures, yielding −$104.7M in free cash flow.
For the complete Operating / Investing / Financing line-item breakdown:
View Full Cash Flow Statement →Free cash flow vs peers (Healthcare)
About Free Cash Flow & Methodology
Century Therapeutics, Inc. (IPSC) reported free cash flow of −$104.7M for FY2025 (fiscal year ending 2025-12-31), up 5.0% year-over-year. The FCF margin was -95.9%.
Century Therapeutics, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 7 fiscal years.
Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.
Frequently asked questions
IPSC free cash flow · 8 questionsCentury Therapeutics, Inc. free cash flow was −$104.7M for FY2025, up 5.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$95.9M.
▸ Source: FMP /cash-flow-statement · US GAAP · Century Therapeutics, Inc. · Century Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026